No Data
No Data
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
WOBURN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced
Replimune to Present at Three Upcoming Investor Conferences
WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapie
Is Replimune Group, Inc. (NASDAQ:REPL) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Replimune Group fair value estimate is US$6.45 Replimune Group's US$8.61 share price signals that it might be 33% overvalued Analyst price
12 Best Medical Stocks to Buy Under $10
Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating
Replimune Group (REPL) has an average rating of outperform and price targets ranging from $10 to $19, according to analysts polled by Capital IQ.
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)
No Data